Form 4: AngioDynamics Director Receives Annual Stock Compensation Grant
Insider Transaction Report
AngioDynamics Inc. Director Howard W. Donnelly was granted 17,675 shares of common stock as part of his regular annual compensation, immediately vesting upon grant.
Summary
- Howard W. Donnelly, a Director of AngioDynamics Inc. (ANGO), acquired 17,675 shares of common stock on July 16, 2025.
- The acquisition represents restricted stock units granted as regular annual compensation for his service as a director.
- The restricted stock units immediately vested at the time of grant, with a transaction price of $0 per share.
- Following this transaction, Mr. Donnelly beneficially owns a total of 167,051 shares of AngioDynamics common stock.
- A Substitute Power of Attorney was executed on January 20, 2025, appointing Lawrence T. Weiss as a substitute attorney-in-fact for Howard Donnelly, superseding previous appointments.
Sentiment
Score: 6
Explanation: The document reports a routine compensation grant to a director, which is a neutral to slightly positive event as it aligns management interests with shareholders. It does not contain information that would significantly alter the company's financial outlook or operational performance.
Positives
- Director Howard W. Donnelly received 17,675 shares of common stock as compensation, increasing his direct ownership in AngioDynamics.
- The shares vested immediately, providing immediate ownership to the director.
- The grant aligns the director's interests with those of the shareholders.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of insider compensation and does not provide broader industry trends or competitive analysis.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Appointment | Stephen A. Trowbridge appointed Lawrence T. Weiss as a substitute attorney-in-fact for Howard Donnelly, superseding any prior substitute powers of attorney. This ensures proper authorization for SEC filings on behalf of the director. | January 20, 2025 | Ensures continuity and proper authorization for SEC filings on behalf of the director. |
Related Party Transactions
- The grant of 17,675 shares of common stock to Director Howard W. Donnelly as regular annual compensation constitutes a related party transaction.
Stakeholder Impact
- Shareholders: Potential minor dilution from the issuance of new shares, but also improved alignment of interests with the director.
- Director (Howard W. Donnelly): Increased equity ownership in the company, enhancing personal stake and potential for wealth creation tied to company performance.
Key Dates
| Date | Description |
|---|---|
| January 20, 2025 | Execution date of the Substitute Power of Attorney appointing Lawrence T. Weiss. |
| July 16, 2025 | Date of the common stock acquisition transaction for Howard W. Donnelly. |
| July 18, 2025 | Date the Form 4 filing was signed by the reporting person's attorney-in-fact. |
Keywords
AngioDynamics, ANGO, SEC Form 4, Insider Transaction, Stock Grant, Director Compensation, Restricted Stock Units, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.